openPR Logo
Press release

Global Breast Cancer Predictive Genetic Testing Market Ongoing Outlook 2022

08-09-2017 06:16 AM CET | Health & Medicine

Press release from: Kuick Resarch

Global Breast Cancer Predictive Genetic Testing Market Ongoing

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

Report Table of Contents

Cancer Susceptibility Testing
1.1 Prologue to Cancer Susceptibility
1.2 Aspects of Cancer Susceptibility Testing

Breast Cancer Susceptibility
2.1 Conceptual of Breast Cancer Susceptibility
2.2 Trail of the Inherited Susceptible Genes

Hereditary Breast Cancer Genes
3.1 High Penetrant Genes
3.1.1 Breast Cancer Gene1 (BRCA1)
3.1.2 Breast Cancer Gene 2 (BRCA2)
3.1.3 TP53
3.1.4 PTEN
3.1.5 STK11 and CDH1
3.2 Intermediate Penetrant Genes
3.2.1 CHEK2
3.2.2 PALB2
3.2.3 ATM
3.2.4 Other Genes
3.3 Low Penetrant Genes

Breast Cancer Susceptible Syndromes
4.1 Hereditary Breast and Ovarian Cancer
4.2 Cowden Syndrome
4.3 Li-Fraumeni Syndrome
4.4 Peutz-Jeghers Syndrome

Cancer Susceptibility Testing Essentials
5.1 Prerequisites towards Cancer Susceptibility
5.2 Sequential Stages in Testing

Genetic Cancer Susceptibility Testing
6.1 Risk Assessment
6.2 Genetic Counseling
6.3 Genetic Testing
6.4 Post-Test Counseling

Management of Hereditary Risk
7.1 Surveillance
7.2 Chemoprevention
7.3 Bilateral Prophylactic Mastectomy

Economical, Ethical and Social Aspects
8.1 Economic Aspects of Cancer Susceptibility Testing
8.2 Ethical Aspects of Cancer Susceptibility Testing
8.3 Social Aspects of Cancer Susceptibility Testing

Global Prevalence of Breast Cancer
9.1 Breast Cancer Incidences
9.2 Germline Breast Cancer Ethnicity

Prevalence over Geographic Regions
10.1 Prevalence in Developed Regions
10.1.1 US
10.1.2 Europe
10.1.3 Canada
10.1.4 Japan
10.2 Prevalence in Developing Regions
10.2.1 China
10.2.2 India
10.2.3 Africa

Preface of Monetary Prospects
11.1 Cost of Breast Cancer Susceptibility Testing
11.2 Insurance Affairs for Breast Cancer Susceptibility Testing

Aspects of Cancer Susceptibility Market
12.1 Breast Cancer Susceptibility Market Overview
12.2 Direct To Consumer Market

Global Breast Cancer Predictive Genetic Testing Market Dynamics
13.1 Accelerative Parameters
13.2 Challenges

Global Breast Cancer Predictive Genetic Testing Market Future Aspects

Competitive Landscape
15.1 Cancer Genetics
15.2 Invitae
15.3 Iverson Genetics
15.4 Myriad Genetics
15.5 NeoGenomics
15.6 Oncocyte
15.7 PerkinElmer
15.8 Quest Diagnostics
15.9 Roche
15.10 Thermo Fisher Scientific

Figure 1-1: Layout of Traditional and Advanced Cancer Susceptibility Testing
Figure 2-1: Demonstration of the Potentials Aspects of the Cancer Susceptibility Testing
Figure 3-1: Common Genetic Variants of Breast Cancer Susceptible Genes
Figure 3-2: Percentage of BRCA1 Gene Mutations and Other Genes for Breast Cancer
Figure 3-3: Breast Cancer Risk by Carriers and Non-Carriers with Growing Age
Figure 3-4: Representation of Gene Specific Lifetime Breast Cancer Risks
Figure 3-5: Percentage of Risk Factors of Breast Cancer and Variability of Penetrance Genes
Figure 4-1: Percentage Share of the Causes of Breast Cancer Risk Assessment
Figure 4-2: Number of Genes Associated With Hereditary Breast Cancer Syndrome
Figure 4-3: The Cumulative Lifetime Risk to Age 70 Years for Breast or Ovarian Cancer
Figure 4-4: Li-Fraumani Syndrome Age Related Risk Patterns for Cancer Development
Figure 5-1: Advantages of Genetic Cancer Susceptibility Tests
Figure 5-2: The Criteria of Target Population for Genetic Testing of Breast Cancer
Figure 5-3: Representation of the Sequential Stages in the Cancer Susceptibility Testing
Figure 6-1: The Concept of Breast Cancer Risk Assessment and Management
Figure 6-2: The Outline of Genetic Test for Breast Cancer Susceptibility
Figure 6-3: Interpretation of Possible Outcomes after Cancer Genetic Testing
Figure 7-1: Management Strategies of Hereditary Risk of Breast Cancer
Figure 7-2: Percentage of Cancer Risk Reductions via Varied Management Strategies
Figure 8-1: Proportion of Cost Effectiveness Ratios in Predictive Genetic Test
Figure 8-2: Ethical Issues of Breast Cancer Susceptibility Testing
Figure 9-1: Global - Demonstration of Incidence and Mortality Rate of Breast Cancer
Figure 9-2: Global - Comparative Percentage of Risk of Developing Breast Cancer in Women
Figure 9-3: US - Prevalence of BRCA Mutation Percentage among White Population
Figure 9-4: UK - Prevalence of BRCA Mutations Percentage among White Population
Figure 9-5: Prevalence of Mutations in Ashkenazi Jewish Individuals
Figure 10-1: US - Rates of Incidence and Mortality Breast Cancer in US as per 100,000
Figure 10-2: US- Prevalence of BRCA1 Mutations Percentage over the Base of Ethnicity
Figure 10-3: Europe - Percentage of Incidence and Mortality of Breast Cancer
Figure 10-4: UK - Rate of Breast Cancer Incidence Related to Age, 2014
Figure 10-5: Europe - Percentage of BRCA1 Mutation in High Risk Families
Figure 10-6: Canada - Percentage of All New Cancer Cases and Breast Cancer Cases, 2016
Figure 10-7: Canada - Percentage of New Breast Cancer Diagnosed in Canadian Women by Age Group, 2016
Figure 10-8: Japan - Incidence Rates of Breast Cancer as per 100,000
Figure 10-9: China - Incidence and Mortality Rates in Chinese Population, 2015
Figure 10-10: India - Percentage of Increasing Incidence of Breast Cancer in Younger Age Groups
Figure 10-11: Central Africa - Age Adjusted Incidence and Death Rates for Breast Cancer
Figure 11-1: US - Cost of Breast Cancer Susceptibility Testing (US$)
Figure 11-2: UK - Cost of Breast Cancer Susceptibility Testing (US$)
Figure 11-3: Canada - Cost Range of Breast Cancer Susceptibility Testing (US$)
Figure 11-4: Japan - Cost Range of Breast Cancer Susceptibility Testing (US$)
Figure 11-5: Australia and New Zealand - Cost of Breast Cancer Susceptibility Testing (US$)
Figure 11-6: China - Cost of Breast Cancer Susceptibility Testing in China (US$)
Figure 11-7: India - Cost of Breast Cancer Susceptibility Testing (US$)
Figure 11-8: Singapore - Cost of BRCA Testing and Mastectomy
Figure 12-1: Myriad’s - Market Sales for BRCA Testing (US$ Millions)
Figure 12-2: Criticism for the BRCA Testing Genes Patented by Myriad Genetics
Figure 12-3: The Cost Comparison of Myriads BRCA Testing and Other Competitors (US$)
Figure 12-4: Price Difference between Healthcare BRCA Testing and Direct to Consumer Test
Figure 12-5: Global andndash; BRCA Susceptibility Testing Market Opportunity (US$ Million), 2017-2022
Figure 12-6: US andndash; BRCA Susceptibility Testing Market Opportunity (US$ Million), 2017-2022
Figure 12-7: Europe andndash; BRCA Susceptibility Testing Market Opportunity (US$ Million), 2017-2022
Figure 12-8: Asia andndash; BRCA Susceptibility Testing Market Opportunity (US$ Million), 2017-2022
Figure 13-1: Global - Major Parameters of Growth in Breast Cancer Susceptibility Testing
Figure 13-2: Global - Major Challenges of Breast Cancer Susceptibility Market


Table 4-1: High Penetrance Mutation Variants Corresponding to Breast Cancer Syndromes
Table 7-1: Schedule of Surveillance of Breast Cancer According To Age

Download Report: https://www.kuickresearch.com/report-global-breast-cancer-predictive-genetic-testing-market-outlook-2022.php

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Breast Cancer Predictive Genetic Testing Market Ongoing Outlook 2022 here

News-ID: 660731 • Views:

More Releases from Kuick Resarch

Lumakras Drug Clinical Insight and Sales Forecast 2026
Lumakras Drug Clinical Insight and Sales Forecast 2026
"Lumakras Drug Clinical Insight and Sales Forecast 2026" Report Highlights: * NSCLC Targeting Lumakras Market Opportunity (US$ Million) * Colorectal Cancer Targeting Lumakras Market Opportunity (US$ Million) * Pharmacokinetics of Lumakras (Sotorasib) * Dosage, Patent and Price Analysis * Lumakras Ongoing Clinical Trials * Global KRAS Protein Inhibitors Clinical Trials Download Report: https://www.kuickresearch.com/report-lumakras-sotorasib-sales-forecast-fda-approved-kras-inhibitor-clinical-trials-non-small-cell-lung-cancer-nslc-g12c-mutation-c30h30f2n6o3-ras-gtpase The rising burden of cancer and the increasing cancer mortality rates possesses an unmet need for the development of novel therapies in the management
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
"Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026" Report Highlights: * Global EZH2 Inhibitor Market Opportunity > US$ 1.2 Billion by 2026 * Tazverik (Tazemetostat) First Approved EZH2 Inhibitor Drug * Dosage, Price and Sales Analysis of Tazverik * Tazverik Sales Opportunity > US$ 900 Million by 2026 * Tazverik Sales Forecast 2021 Till 2026 * EZH2 Inhibitor Clinical Pipeline Overview By Company, Indication and Phase * EZH2 Inhibitor in Clinical Trials: 7 Drugs Download
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Tr …
"Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028" Report Highlights: * Global Bispecific Antibody Market Opportunity: > US$ 20 Billion * Global Bispecific Antibody Market Growth Rate: 100% CAGR (2016 -2021) * Approved Bispecific Antibodies In Market: 4 Antibodies * Detailed Market Sales and Trends Insight Till 2028 * Quarterly and Yearly Sales Insight Of Approved Antibodies Till Q1 2022 * Global and Regional Market Analysis * Approved Drug Sales
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and C …
"Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026" Report Highlights: * Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026 * Role of FGFR Inhibitors in Cancer Therapy * Global FGFR Market Assessment (US$) by Region and Cancer Type Clinical and Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre and Truseltiq) * Dosage and Drug Price Insight on Approved FGFR Inhibitors * Comprehensive Clinical Trials Insight

All 5 Releases


More Releases for Cancer

Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose. Increase in incidence of target diseases like cancer is key driving factor which is expected to boost
Oncology Nutrition Market led to an unprecedented rise by 2025 : liver cancer, p …
Global Oncology Nutrition Market: Overview Cancer diagnosis creates myriad questions about diet and nutrition. Those pertain to if the food will make a patient feel sick to what should be ingested to fight cancer. This has spawned the oncology nutrition market which has been rising steadily due to the increasing cases of different types of cancer worldwide. During cancer treatment one needs to eat right in order to build up strength
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business. Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine. These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch
Cancer Diagnostics Global Market: By Application - Breast Cancer, Lung Cancer, C …
Researchmoz added Most up-to-date research on "Cancer Diagnostics Global Market: By Application - Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma & Other Cancers" to its huge collection of research reports. This report studies Cancer Diagnostics in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top